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Objective: to assess the epidemiology and features of de novo surgical diseases in patients
admitted with COVID-19, and their impact on patients and healthcare system.
Summary background data: Gastrointestinal involvement has been described in COVID-19;
however, no clear figures of incidence, epidemiology and economic impact exist for de-
novo surgical diseases in hospitalized patients.
Methods: This is a prospective study including all patients admitted with confirmed SARS-
CoV-2 rT-PCR, between 1 March and 15 May 2020 at two Tertiary Hospitals. Patients with
known surgical disease at admission were excluded. Sub-analyses were performed with a
consecutive group of COVID-19 patients admitted during the study period, who did not
require surgical consultation.
Results: Ten out of 3089 COVID-19 positive patients (0.32%) required surgical consultation.
Among those admitted in intensive care unit (ICU) incidence was 1.9%. Mortality was 40%
in patients requiring immediate surgery and 20% in those suitable for conservative man-
agement. The overall median length of stay (LOS) of patients admitted to ICU was longer in
those requiring surgical consultation compared with those who did not (51.5 vs 25 days,
p ¼ 0.0042). Patients requiring surgical consultation and treatment for de-novo surgical
disease had longer median ICU-LOS (31.5 vs 12 days, p ¼ 0.0004). A median of two post-
surgical complications were registered for each patient undergoing surgery.
Complication-associated costs were as high as 38,962 USD per patient.
Conclusions: Incidence of de-novo surgical diseases is low in COVID-19, but it is associated
with significant morbidity and mortality. Future studies should elucidate the mechanism
underlying the condition and identify strategies to prevent the need for surgery.
© 2020 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and
Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.Introduction
The outbreak of Severe Acute Respiratory Syndrome Corona-
virus 2 (SARS-COV-2) was initially detected in Wuhan, capitalnit, Hospital Vall d’Hebr
spı́n-Basany).
cidence, features, outcom
9, The Surgeon, https://d
of Edinburgh (Scottish ch
.
of Hubei, province of China in December 20191e3 as pneu-
monia of unknown origin. On January 8th the novel Corona-
virus was officially announced as the causative pathogen by
the Chinese Centre for Disease Control and Prevention4 and it
was namedCoronavirus disease 2019 (COVID-19) by theWorldon, Paseo Valle de Hebron 119-129, Barcelona, 08035, Spain.
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t h e s u r g e on x x x ( x x x x ) x x xe2Health Organization (WHO) in February of 2020.5 On March
12th the WHO declared COVID-19 a pandemic.6 More than 26
million people have been infected, with over 864,000 deaths.7
Hospitalized patients requiring ICU admission are calculated
around a 25%.8
In relation to surgery, poorer outcomes are associated after
surgery in COVID-19-positive patients. Up to 44% of patients
undergoing elective surgery during the COVID-19 incubation
period might need postoperative Intensive Care Unit (ICU)
care, with a mortality rate of 20.5%.9 Hence, most surgical
societies recommend conservativemanagement of COVID-19-
positive patients presenting with some urgent surgical dis-
eases.10,11 COVID-19 patients might develop de-novo surgical
diseases during hospitalization, requiring surgical consulta-
tion and treatment.
Spain is currently themost affected country in Europewith
488,513 confirmed cases and 29,234 death by the 3rd
September 2020.7,12 Recent reports suggest that, in Catalonia
Region, the toll of deaths related to COVID-19 exceeded 12,954
cases, when fatalities based on data from funeral services are
taken into account.13 Reporting on the Spanish experience
could be useful at a time when some countries have not yet
“flattened the curve” and new infection waves are predicted.
This study aims to assess the epidemiology, features,
economic burden and outcome of late-onset surgical diseases
in patients treated for COVID-19 in two Catalan hospitals, one
of the most affected regions in Spain.Methods
This is a prospective, STROBE-compliant, observational study
performed at Vall d’Hebron University Hospital and Bellvitge
University Hospital. Ethical Committee approval was
obtained.
Eligibility criteria
All hospital admitted patients, 18-years-old or older, with
confirmed COVID-19 were prospectively assessed for inclusion
(March 1eMay 15). Patients who required surgical consultation/
review during admission were identified. Patients who were
admitted with a known surgical disease were not included, as
well as patients without confirmed diagnosis of COVID-19.
Endpoint and outcome of interest
The primary endpoint was the incidence of late-onset surgical
diseases in COVID-19 positive patients, the associated
morbidity and outcome. All complications occurring after
consultation and any therapies by the surgical team were
used as outcome measures.
The secondary endpoints included mortality and the esti-
mated costs associated with the complications.
Definitions
Collected data included demographics, underlying comor-
bidities and medications, date of hospitalization and
discharge, testing pathway and date, length of stay, length ofPlease cite this article as: Kraft M et al., Incidence, features, outcom
diseases in patients admitted with COVID-19, The Surgeon, https://dICU stay, medical treatment received for COVID-19, date of
surgical consultation, treatment received for the surgical
condition, treatment results, surgical complications, mortal-
ity cause and date. In all patients included in the analysis who
were admitted to ICU, ICU admission was due to COVID-19.
COVID-19 diagnosis was confirmed by SARS-CoV-2 reverse
transcriptase-polymerase chain reaction (RT-PCR) testing
with throat and nasal swab samples. In some patients, a chest
CT was initially performed,14 with posterior RT-PCR
confirmation.
Consultation and treatment for the following surgical dis-
eases during hospitalization were included: bowel ischemia
and/or perforation, bowel obstruction, appendicitis, chole-
cystitis, pancreatitis, peritonitis, and additional disease of
surgical interest.
All surgical treatments were assessed, including watchful
monitoring, medical therapy (e.g. antibiotics or any review/
modification of current treatment by the surgical team),
percutaneous drainage, and surgery. Surgical assessment of
included patients always included imaging or surgery. Com-
plications were graded according the Clavien-Dindo classifi-
cation15 and the Comprehensive Complication Index (CCI)
score.16
The complication costs were determined by CCI class for
each procedure performed and patient age using the Asses-
sSurgery tool (AssessSurgery.com).
Statistical analysis
Categorical data are presented as absolute numbers and per-
centages, whereas continuous variables are presented as
median with ranges. A descriptive analysis was performed to
report on the incidence and outcomes of de novo surgical
diseases.
The overall incidence was computed by determining the
rate of patients requiring surgical consultation among the
entire number of patients who were admitted for COVID-19 at
both Centers in the study period. Sub-analyses were per-
formed to assess the LOS and outcomes in patients who
needed ICU stay in the group who developed de-novo surgical
disease during admission vs. a consecutive group of COVID-19
patients who did not require surgical consultation. For the
control group, only patients with completely available data
were considered.
The Fisher's exact test was used to compare categorical
data, whereas the ManneWhitney U test was used for
continuous data. A p value < 0.05 was considered statistically
significant.Results
Between March the 1st and May the 15th 2020, 3089 patients
were admitted with proven COVID-19 with no signs or
symptoms of abdominal surgical diseases at both hospitals; of
which 12 (0.39%) required surgical consultation. One patient
was excluded from the final analysis because a CT scan ruled
out appendicitis and another because surgical consultation
was required because of an iatrogenic injury. Therefore, 10
patients required surgical consultation and treatment,e and impact on health system of de-novo abdominal surgical
oi.org/10.1016/j.surge.2020.08.006
Pa ents hospitalized because of COVID-19
Vall d’Hebron University Hospital
(n = 1673)
Pa ents hospitalized because of COVID-19
Bellvitge University Hospital
(n = 1416)
Total pa ents hospitalized because of COVID-19
(n = 3089)







- 1: CT-scan discarded appendici s
- 1: iatrogenic injury
Bowel ischemia and perfora on (n = 4)
Acute Cholecys s (n = 2)
Acute Pancrea s (n = 2) 
Perforated colon carcinoma (n = 1)
Perforated diver culi s (n = 1)
Fig. 1 e Flowchart.
t h e s u r g e on x x x ( x x x x ) x x x e3accounting for 0.32% of admitted patients with COVID-19.
When only patients already admitted to the ICU were
considered, the incidence was 1.9% (8/409).
Out of 10 patients who required consultation, four (40%, 4/
10) were diagnosed with bowel ischemia and perforation, two
(20%, 2/10) with acute cholecystitis, two (20%, 2/10) with acute
pancreatitis, one (10%, 1/10) with perforated colon carcinoma,
and one (10%, 1/10) with perforated diverticulitis. Flowchart of
patient selection is represented in Fig. 1.
Patient characteristics are detailed in Table 1. A median of
18 (3e28) days passed between admission and surgical
consultation.Please cite this article as: Kraft M et al., Incidence, features, outcom
diseases in patients admitted with COVID-19, The Surgeon, https://dThe reason for consultation is reported in Table 2, along
with therapeutic decisions and outcomes.
Out of four patients with bowel ischemia, this occurred in
the right colon/terminal ileum in two (50%, 2/4), and at the
transverse colon in one (25%, 1/4), whereas one patient had
massive small bowel ischemia due to mesenteric arterial
thrombosis that could not be treated by interventional radi-
ology. The latter patient was offered palliative treatment,
whereas the other three were operated on. Overall, five pa-
tients had a bowel perforation, and all underwent open sur-
gery with no anastomosis, because of clinical instability. One
of them (20%, 1/5) died within 24 h from surgery because ofe and impact on health system of de-novo abdominal surgical
oi.org/10.1016/j.surge.2020.08.006
Table 1 e Characteristic of patients who required surgical
consultation during admission for COVID-19.
Characteristics Patients (n ¼ 10)
Age, yr median 63.5 (46e72)
Male 6 (60%)
BMI, kg/m2 median (range) 28.2 (23.9e49.4)
Comorbidities
Peripheric vascular disease 1 (10%)
Dementia 1 (10%)
COPD 1 (10%)
Diabetes mellitus 1 (10%)
Peptic ulcer disease 1 (10%)










SARS-CoV-2 RT-PCR testing 10 (100%)
Length of stay, days median (range) 44.5 (11e108)
Length of ICU stay, days median (range) 28.5 (0e104)
Length of stay before surgical consultation,
days median (range)
18 (3e28)
BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Dis-
ease; ASA: American Society of Anesthesiologists' score; ICU:
Intensive Care Unit.
t h e s u r g e on x x x ( x x x x ) x x xe4multi-organic sepsis. One patient (20%, 1/5) with perforated
colon cancer died after myocardial infarction, five weeks after
surgery.
Two patients were diagnosed with acute cholecystitis and
underwent cholecystostomy. Two patients were diagnosed
with acute pancreatitis, one of them with a 16-cm collection.
Watchful monitoring was decided, which proved successful,
with clinical and radiological improvement in subsequent CT
scans.
The pathology report of the patient with the perforated
colon cancer was consistent with a G2, pT3N0 adenocarci-
noma with a 30% mucinous component. Perforation and in-
vasion of small vessels was found. In two of the three
ischemic perforations, involvement of small and medium
vessels was observed, and micro-thrombosis in one.
Thirteen complications occurred in the five patients who
underwent surgery, with a median of two (range 1e4) com-
plications per patient. These ranged from wound infection to
multi-organ failure and death (Table 2). Each patient devel-
oped at least one complication.
The overall median LOS was 44.5 (range 11e108), the me-
dian LOS in ICU was 28.5 (0e104) days.
LOS and mortality of patients admitted to ICU who
required surgical consultation were compared with a
consecutive group of 272 patients who were admitted to ICU
for COVID-19 and did not require surgical consultation. The
overall median LOS of those admitted to ICU was longer in
those who required surgical consultation, being 51.5 (range
18e108) vs 25 (range 2e72) days, surgical consultation group
vs. controls (p ¼ 0.0042). Patients who needed surgicalPlease cite this article as: Kraft M et al., Incidence, features, outcom
diseases in patients admitted with COVID-19, The Surgeon, https://dconsultation and treatment for de-novo surgical diseases had a
median of 19.5 days longer LOS in ICU comparedwith controls
(31.5 [range 18e104] vs. 12 [1e62] days, p ¼ 0.0004).
Overall, mortality was 30% (3/10). Among those who
needed immediate surgery, mortality was 40% (2/5) and 20%
(1/5) in those suitable for conservativemanagement. Mortality
in patients who required surgical consultation during their
ICU staywas 37.5% (3/8), whichwas higher but not statistically
different from mortality in the control group of patients who
did not require surgical consultation (20.22%, 55/272,
p ¼ 0.369).
Overall, the costs associated with the surgical complica-
tions were as high as 311,703 USD, withmedian costs of 38,962
(range 27,365e80,871) USD for each operated patient.Discussion
In this study, the overall incidence of de-novo surgical disease
in hospitalized patients for COVID-19 was 0.32% in two ter-
tiary hospitals during the peak phase of the pandemic, which
increased to 1.9% when only considering patients already
admitted in ICU for COVID-19. Mortality in thosewho required
surgery was twice as high as that previously reported in
COVID-19 patients presenting with abdominal diseases. The
onset of de-novo surgical diseases negatively impacts on
hospital resources, increasing the overall LOS and stay in ICU,
and postoperative complications, which are frequent in this
group of patients. This significantly increases the care asso-
ciated costs.
Previous studies on non-COVID-19 patients reported that
approximately 1e1.5% of patients in ICU develop an ICU-
acquired abdominal sepsis.17 It has been suggested that late-
onset abdominal sepsis accounts for 15% of all cases of
abdominal sepsis in ICU.18 We found that the incidence of
abdominal complications not present at the time of admission
is overall negligible in confirmedCOVID-19-patients; however,
in the subgroup of patients admitted to ICU, the rate is higher.
A study on 141 critically-ill COVID-19 patients, found that five
needed surgery for abdominal conditions (3.5%), mainly rep-
resented by bowel ischemia19; when only cases with no signs/
symptoms of abdominal disease at admission are evaluated,
the rate might be lower. Gastrointestinal involvement is
common in COVID-19 patients in ICU, and may be managed
with conservative approach depending on the involved pa-
thology and the diseases progression.19
Involvement of small vessels and viral entero-neuropathy
has been suggested to occur in COVID-19 patients, and might
be responsible for the relatively high number of patients with
bowel ischemia and ileus.19 In our series, all patients with
bowel perforation had involvement of small vessels at pa-
thology, suggesting that the virus itself might be responsible
for the condition rather than the treatments delivered. Even if
the small sample size does not allow definitive conclusions,
future studies shouldelucidate thepathophysiologyof surgical
diseases in patients with COVID-19.
The overall number of COVID-19 patients who need sur-
gical consultation for de-novo surgical disease is low, but there
are aspects that need to be carefully considered and might be
relevant.e and impact on health system of de-novo abdominal surgical
oi.org/10.1016/j.surge.2020.08.006
Table 2 e Reason for surgical consultation and outcome, including costs associated with complications.







1 62 F 29.2 None 2 1 76 66 Bowel ischemia e perforation Right
Hemicolectomy
2 33.2 31,742 USD ARDS, GBS, PTE No
2 72 M 28.6 Diabetes
mellitus
4 2 54 47 Perforated colon cancer Right
Hemicolectomy




3 57 F 25,9 COPD 2 3 18 18 Bowel ischemia e perforation Right
Hemicolectomy
5 100 80,871 USD ARDS, ARF, CRS Yes
4 64 M 24.6 None 2 1 40 29 Acute biliary Pancreatitis Watchful
monitoring
e e e ARDS, PTE þ PVT,
Pneumothorax,
No
5 62 M 49.4 None 2 2 21 18 MAT þ massive bowel ischemia Symptom
control/palliation
e e e ARDS, PTE þ PVT Yes
6 72 M 29.8 Dementia,
Hypophysis
adenoma
6 3 49 28 Perforated Diverticulitis Hartmann
Procedure
2 22.6 30,854 USD ARDS No
7 60 M 27.8 Peripheral
Vascular Disease
3 2 11 0 Acute biliary Cholecystitis Percutaneous
Cholecystostomy
e e e None No
8 69 F 23.9 None 2 2 108 104 Bowel ischemia e perforation Transverse
Colectomy
2 22.6 27,365 USD ARDS, myopathy,
BSI
No
9 65 M 25.9 None 2 1 63 34 Acute biliary Cholecystitis Percutaneous
Cholecystostomy
e e e PTE, Ischemic
colitis, BSI
No
10 46 F 29.9 PUD, Ulcerative
Colitis
1 1 14 0 Non-biliary Acute Pancreatitis Watchful
monitoring
e e e None No
BMI: Body Mass Index; LOS: Length of stay; ICU: Intensive care unit; CD: Clavien-Dindo classification; CCI: cumulative complication index; F:
Female; M: Male; ARDS: Acute Respiratory Distress Syndrome; GBS: Guillain Barre Syndrome; PTE: Pulmonary thromboembolism; ARF: Acute
Renal Failure; COPD: Chronic Obstructive Pulmonary Disease; CRS: Catheter-related sepsis; PVT: Peripheral Vascular Thrombosis; MAT:
Mesenteric Arterial Thrombosis; BSI: Bacterial Superinfection; PUD: Peptic Ulcer Disease.
t h e s u r g e on x x x ( x x x x ) x x x e5Complications are common in patients who undergo sur-
gery during COVID-19 infection, and all patients in this series
developed at least one complication. Postoperative mortality
has been reported to occur in almost 24% of COVID-19-positive
patients.19 Even in patients undergoing elective surgery with
known diagnosis of COVID-19 death rate is non-negligible
(9.1%).20 Figures might be higher when de-novo surgical dis-
eases occur, with up to 37.5% mortality in ICU patients with
COVID-19. Differently from the usual causes of death reported
in COVID-19 patients, mainly pulmonary complications,8,20 in
this series, most patients died as a consequence of systemic
sepsis. Compared with COVID-19 patients in ICU who did not
require surgical consultation,mortalitywas almost doubled in
those who required input from the surgical team, but the
small sample size should be taken into account (p¼0.369).
Discussing care-associated cost might be useful, given the
resource shortage that has been reported during the mitiga-
tion phase, and the backlog of procedures that need to be
performed in the upcoming months.21 It has been estimated
that COVID-19 will cause 654.0 USD billion in direct costs in
the US over the course of the pandemic should 8% of the
population be infected.22
Early predictions in Spain suggested that 1800 billion Euros
would be required to face the pandemic.23 Mechanical venti-
lation is associated with incremented costs, which are already
high in COVID-19 patients. The first two days are usually the
most expensive as mechanical ventilation is often needed,
whereas costs become more stable from day 3 of ICU stay
(mechanical ventilation, 3968 USD; nomechanical ventilation,
3184 USD).24 In our series, the LOS in ICU was in median
almost 3 weeks longer in patients with de novo surgical disease
compared with patients who did not need surgicalPlease cite this article as: Kraft M et al., Incidence, features, outcom
diseases in patients admitted with COVID-19, The Surgeon, https://dconsultation (p ¼ 0.0004). This generate much higher costs
than can be predicted, since e after surgery e patients may
need prolonged use of ventilators.
Postoperative complications add to the aforementioned
costs. A median of two complications per patient occurred
in the patients who underwent surgery, meaning that the
costs for each patient increased by approximately 38,962
USD.
Study limitations
The relatively small sample size requires that findings are
interpreted with caution. The cost estimates were approxi-
mated and might have been higher in the context of the
pandemic.
However, this study was conducted prospectively on pa-
tients from two of the larger tertiary centres in Spain, with
high volume of COVID-19 patients treated. Incidence could be
reliably estimated, and the morbidity and complication-
associated costs might be useful in managing patients with
such presentation.
The incidence of de-novo surgical disease is low in COVID-
19, similar to non-COVID-19 critically ill patients. However,
clinical symptoms should be detected and surgical review
obtained, due to unacceptably high associated morbidity and
mortality. Surgical treatment prolongs admission in ICU and
increases costs of care. Conservative treatment is a safe op-
tion, when possible.
Future studies should elucidate themechanismunderlying
the condition, e.g. hypercoagulability and thrombo-
inflammation in COVID-19 patients,25e27 and identify strate-
gies to prevent the need for surgery.e and impact on health system of de-novo abdominal surgical
oi.org/10.1016/j.surge.2020.08.006
t h e s u r g e on x x x ( x x x x ) x x xe6Informed consent
Informed oral consent was obtained from all individual par-
ticipants included in the study, following the recommenda-
tions of our ethical committees due to the pandemic.Declaration of Competing Interest
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